Nasdaq tmdx.

ANDOVER, Mass., July 30, 2019 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for ...TransMedics (“TMDX”), headquartered in Andover, MA, is a leader in normothermic machine perfusion technology utilized for organ preservation during the organ transplant process. TransMedics ...That number of contracts represents approximately 208,500 underlying shares, working out to a sizeable 47.2% of TMDX's average daily trading volume over the past month, of 441,660 shares.Earnings for TransMedics Group are expected to decrease in the coming year, from ($0.34) to ($0.67) per share. TransMedics Group has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 28th, 2024 based off prior year's report dates. Read More.Nov 10, 2023 · TransMedics (TMDX) reported $66.43 million in revenue for the quarter ended September 2023, representing a year-over-year increase of 158.7%. EPS of -$0.12 for the same period compares to -$0.25 a ...

ANDOVER, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients ...Target price 65.415. Change. Ends at 07.11.24. TransMedics Group, Inc. (NASDAQ: TMDX) had its price target raised by analysts at JPMorgan Chase & Co. from $67.00 to $70.00. They now have an "overweight" rating on the stock. Ratings data for TMDX provided by MarketBeat.TransMedics Group (NASDAQ:TMDX) provides organ preservation technology and is a leader in normothermic machine perfusion.Its FDA-approved Organ Care System replicates the body’s physiologic ...

In recent trading, shares of TransMedics Group Inc (Symbol: TMDX) have crossed above the average analyst 12-month target price of $78.60, changing hands for $79.05/share. When a stock reaches the ...

FDA's Circulatory System Devices Panel of the Medical Devices Advisory Committee will meet April 6 to discuss TransMedics Group, Inc.'s (NASDAQ:TMDX) premarket approval application for the ...Nov 7, 2023 · 57.37. -0.89. -1.53%. TransMedics Group, Inc. (NASDAQ:TMDX) Q3 2023 Earnings Call Transcript November 6, 2023 Operator: Good afternoon, and welcome to TransMedics Third Quarter 2023 Earnings ... ANDOVER, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients ...TransMedics Group (NASDAQ: TMDX) announced that NASDAQ has halted the trading of its common stock ahead of an FDA AdCom meeting scheduled for today at 9.00 AM EST to review its Organ Care System ...TransMedics’ (NASDAQ: TMDX) Organ Care System is utilized “for preserving organs used in the treatment of end-stage heart, lung, and liver failure.”

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today ...

२०२३ अगस्ट २ ... (NASDAQ: TMDX), including its EVOSS heart and lung and LifeCradle heart perfusion assets. BTL will use the proceeds from the divestiture of ...

According to the issued ratings of 8 analysts in the last year, the consensus rating for TransMedics Group stock is Moderate Buy based on the current 1 hold rating and 7 buy ratings for TMDX. The average twelve-month price prediction for TransMedics Group is $79.83 with a high price target of $110.00 and a low price target of $54.00.ANDOVER, Mass., Nov. 3, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on November 1, 2023, TransMedics granted non-qualified stock options to purchase an …TransMedics Group, Inc. (NASDAQ:TMDX) is a Massachusetts-based commercial-stage medical technology company, engaged in transforming organ transplant therapy for end-stage organ failure patients in ...Aug 1, 2022 · NasdaqGM:TMDX Earnings and Revenue Growth August 1st 2022. Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences ... ANDOVER, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients ...TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today ...TMDX stock has a Moderate Buy consensus rating based on two Buy and one Hold recommendations. However, due to the recent rally in its stock price, analysts’ average price target of $66.67 ...

Feb 17, 2023 · TMDX stock has a Moderate Buy consensus rating based on two Buy and one Hold recommendations. However, due to the recent rally in its stock price, analysts’ average price target of $66.67 ... ANDOVER, Mass., Aug. 9, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with ...We note that TransMedics Group, Inc. (NASDAQ:TMDX) does have debt on its balance sheet. But the real question is whether this debt is making the company risky. But the real question is whether ...TransMedics Group press release (NASDAQ:TMDX): Q3 GAAP EPS of -$0.78 misses by $0.59.; Revenue of $66.4M (+158.4% Y/Y) beats by $17.22M. Shares +14.46%.; Closed acquisition of Summit Aviation ..."The third quarter was a critical execution period for TMDX as we integrated a new business, expanded our NOP clinical support capacity, and launched a first-of-its kind business to expand our NOP ...2023年11月7日 上午10:15 · 16 分鐘文章. TransMedics Group, Inc. (NASDAQ: TMDX) Q3 2023 Earnings Call Transcript November 6, 2023. Operator: Good afternoon, and welcome to TransMedics Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. We will be facilitating a question-and-answer ...

Establishes the first national provider of air logistics dedicated to organ transplantation in the U.S.. ANDOVER, Mass., Aug. 1, 2023 /PRNewswire/ -- TransMedics Group, Inc. (" TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver …

Dec 1, 2023 · The list of insiders at TransMedics Group includes Abrams Capital Management, L.P, David Weill, Edward M Basile, Edwin M Kania Jr, James R Tobin, John F Carey, John F Sullivan, Laura Damme, Miriam Provost, Stephanie Lovell, Stephen Gordon, Tamer I Khayal, and Waleed H Hassanein. May 21, 2023 · COGS surged from $9 million in 2020 to $28.2 million in 2022, while operating expenses surged from $43 million in 2020 to $96.7 million in 2022. However, there's some good news in terms of the ... Nov 30, 2023 · See the latest TransMedics Group Inc stock price (TMDX:XNAS), related news, valuation, ... TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) ANDOVER, Mass., May 1, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2023. Recent Highlights Net revenue of …Nov 21, 2022 · That number of contracts represents approximately 208,500 underlying shares, working out to a sizeable 47.2% of TMDX's average daily trading volume over the past month, of 441,660 shares. View Premium Services. Real time TransMedics Group (TMDX) stock price quote, stock graph, news & analysis.

ANDOVER, Mass., April 21, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with ...

ANDOVER, Mass., Nov. 6, 2023 /PRNewswire/ — TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended September 30, 2023.

Transmedics Group Inc (NASDAQ:TMDX) · Latest TMDX News | Press Releases · Today's Trading · Growth & Valuation · Competitors · Financials · Profile · Forecasts.ANDOVER, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients ...TMDX’s goal is to have 10-15 planes by operation in H1-24, and each plane typically costs $10-$12m (TMDX does not plan to lease the planes), so you could be potentially looking at capital costs ...Aug 8, 2023 · TMDX has in fact been one of my best-performing positions in the last 18 months, running up the page from ~$22 to $80 at the time of writing, some 263% appreciation of capital. ANDOVER, Mass., May 06, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients ...Title. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result ...Nov 3, 2022 · ANDOVER, Mass., Nov. 3, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with ... TransMedics Group, Inc. Prices $400 Million of Convertible Senior Notes Due 2028. ANDOVER, Mass. , May 8, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-st... 7 months ago - PRNewsWire.Swiss National Bank grew its position in TransMedics Group, Inc. (NASDAQ:TMDX – Free Report) by 8.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC).The firm owned 70,900 shares of the company’s stock after purchasing an additional 5,400 …ANDOVER, Mass., March 17, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for ...

TransMedics Group, Inc. Common Stock (TMDX) Earnings Report Date | Nasdaq. Created with Sketch. Zacks earnings numbers are reported on a BNRI (Before Non Recurring Items) basis and include stock ... Contact Data Gerry Haines, CFO (Investor Relations) Impulse Dynamics 856-642-9933 [email protected] Rex Richmond, Director (Media Relations) Impulse Dynamics 856-642-9933 rrichmond ...ANDOVER, Mass., Sept. 7, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with ...Nike, Inc. has no single specific owner. According to Nasdaq, the company is a publicly traded one, with its shares listed on the New York Stock Exchange under the symbol NKE. As of May, 2014, 83.29 percent of Nike’s shares were owned by in...Instagram:https://instagram. price of silver 1980declining us dollart stock dividend historyvortex energy corp stock Contact Data Gerry Haines, CFO (Investor Relations) Impulse Dynamics 856-642-9933 [email protected] Rex Richmond, Director (Media Relations) Impulse Dynamics 856-642-9933 rrichmond ... best real time stock chartsbiggest pre market gainers Find the latest SEC Filings data for TransMedics Group, Inc. Common Stock (TMDX) at Nasdaq.com.In trading on Friday, shares of TransMedics Group Inc (Symbol: TMDX) entered into oversold territory, hitting an RSI reading of 28.7, after changing hands as low as $58.29 per share. By comparison ... leslie pool stock 01:59 PM ET 11/30/2023. Recent sentiment around Nvidia ( NVDA) stock is pointing to signs the stock is set for consolidation. But Dow Jones Industrial Average component …TransMedics Group (NASDAQ: TMDX) announced that NASDAQ has halted the trading of its common stock ahead of an FDA AdCom meeting scheduled for today at 9.00 AM EST to review its Organ Care System ...